Veradermics (MANE) Common Equity (2024 - 2026)

Veradermics (MANE) has 3 years of Common Equity data on file, last reported at $390.6 million in Q1 2026.

• For the quarter ending Q1 2026, Common Equity rose 743.91% year-over-year to $390.6 million; the trailing twelve-month figure through Mar 2026 stood at $390.6 million (up 743.91% YoY), and the FY2025 full-year result was -$121.0 million, down 149.62% from the prior year.
• Common Equity for Q1 2026 stood at $390.6 million, up from -$121.0 million in the prior quarter.
• Across five years, Common Equity topped out at $390.6 million in Q1 2026 and bottomed at -$121.0 million in Q4 2025.
• The 3-year median for Common Equity is -$54.6 million (2024), against an average of $40.1 million.
• The widest annual swing landed in 2025, when Common Equity sank 149.62%; it then soared 743.91% in 2026.
• A 3-year view of Common Equity shows it stood at -$48.5 million in 2024, then tumbled by 149.62% to -$121.0 million in 2025, then jumped by 422.81% to $390.6 million in 2026.
• The last three Common Equity figures came in at $390.6 million (Q1 2026), -$121.0 million (Q4 2025), and -$60.7 million (Q1 2025), per Business Quant data.

Peer Comparison